Business Context and Reporting Period
Company: ReWalk Robotics Ltd. (Note: Metadata listed "Lifeward Ltd." but filing text confirms ReWalk Robotics Ltd.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2017
Reporting Period: Preliminary results for the three and nine months ended September 30, 2017.
Business Overview: Developer of robotic exoskeletons for spinal cord injury (SCI) patients and a new "soft suit" system for stroke rehabilitation.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2017 | Nine Months Ended Sept 30, 2017 | Nine Months Ended Sept 30, 2016 |
|---|---|---|---|
| Revenue | $1.7 million | $6.2 million | $4.3 million |
| Units Placed | 16 | 84 | 80 |
| Insurance-Covered Placements | 7 | 34 | 41 |
| Cash and Equivalents (as of Sept 30, 2017) | $12.9 million | ||
| Accumulated Deficit (as of June 30, 2017) | $119 million |
Geographic Revenue Mix (9 Months 2017): United States (68%), Europe (32%).
Profitability: The filing does not provide specific net income or loss figures for the period, noting only that further losses are anticipated and an accumulated deficit of $119 million existed as of June 30, 2017.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $6.2 million for the nine months ended Sept 30, 2017, compared to $4.3 million in the prior year period. This was driven by sales mix changes, specifically higher sales to the U.S. Veterans' Administration (VA) for a clinical study and increased conversion of rental units to purchases.
- Unit Placements: Total units placed increased slightly to 84 (9 months 2017) from 80 (9 months 2016), though insurance-covered placements decreased to 34 from 41.
- Cash Position: Cash decreased to $12.9 million as of Sept 30, 2017, down from $23.7 million at year-end 2016, though up slightly from $12.4 million in Sept 2016.
- Insurance Claims: Pending insurance claims increased to 218 as of Sept 30, 2017, from 149 in the prior year.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Product Development: Pre-clinical testing began in October 2017 for the "Restore" system (soft suit for stroke patients). A prospective clinical trial is targeted for early 2018, with commercialization in Europe and the U.S. planned for late 2018/early 2019, subject to CE mark and FDA clearance.
- Insurance Strategy: Secured coverage confirmation from BARMER GEK in Germany (covering ~10 million people). Continuing efforts to secure U.S. commercial and CMS (Medicare/Medicaid) coverage.
- Cost Reduction: Goal to reduce total operating expenses in 2017 by up to 30% compared to 2016, including staffing realignment.
- Equity Exchange: Completed a program exchanging "underwater" stock options for Restricted Share Units (RSUs) to restore retention value. 96.4% of eligible options were tendered.
Risks and Contingencies
- Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern due to the $119 million accumulated deficit and anticipated future losses. Future financing is required.
- Capital Raising Limitations: Due to Form S-3 limitations, the company can only issue up to $4.3 million in primary offerings over the next 12 months. Additional capital may require more costly private placements or Form S-1 filings.
- Regulatory (FDA): The mandatory postmarket surveillance study for the ReWalk Personal 6.0 is labeled "inadequate" by the FDA due to slow patient enrollment (only 7 enrolled vs. protocol estimates). Failure to meet requirements could result in marketing restrictions or cessation of U.S. sales.
- Legal: Three securities class action lawsuits remain pending regarding the IPO. No litigation reserve has been recorded as losses cannot be reasonably estimated.
- Delisting Risk: Shares were transferred to the NASDAQ Capital Market. If the closing bid price remains below $1.00 for 30 consecutive days, the company faces delisting proceedings.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $12.9 million cash balance against the $119 million accumulated deficit and the $4.3 million S-3 issuance cap.
- FDA Surveillance Study: Monitor progress on patient enrollment for the mandatory postmarket study; failure could halt U.S. revenue (68% of total).
- Insurance Reimbursement: Track the status of pending claims (218) and the outcome of negotiations with U.S. commercial insurers and CMS.
- Legal Exposure: Review developments in the three pending securities class action lawsuits.
- Stock Price: Monitor share price relative to the $1.00 NASDAQ Capital Market minimum bid requirement to assess delisting risk.